MENOPAUSE MATTERS PRACTITIONERS AREA.
The aim of this section of Menopause Matters is to help therapies to be chosen and adjusted appropriately when treatment is considered necessary, after full consideration of the individual's symptoms and likely benefits and risks of treatment. For many women, the first treatment choice will prove to be effective without side-effects but in others, several adjustments may be necessary. Menopause Matters, along with resources from the British Menopause Society, aims to facilitate this process.
For online menopause learning for healthcare professionals, sign up for IMPART at https://www.imsociety.org/imsimpart_register.php
Aimed at both primary care practitioners and hospital specialists, IMPART delivers evidence-based educational material to improve women’s health care around and after the menopause.
Further update on HRT supply shortages - 27 January 2020
There continues to be availability issues with many HRT products related to manufacturing shortages or supply issues. The BMS has been informed that these are temporary shortages, which pharmaceutical companies and their suppliers are addressing.
See the stock availability pdf here
Further update on HRT supply shortages - 23 September 2019
The British Menopause Society has produced this further update on the current availability of HRT products in response to the ongoing HRT shortages. The objective of this is to provide guidance to BMS members and clinical practitioners who may be experiencing difficulties with HRT supplies.
There continues to be availability issues with many HRT products, either related to manufacturing shortages or supply issues. The BMS has been informed that these are temporary shortages which pharmaceutical companies and their suppliers are addressing. The BMS has been in discussion with the manufacturers as well as the RCOG, FSRH and the Medicine Supply Team at the Department of Health and Social Care to explore this ongoing issue and to provide up to date information on HRT product availability.
In the meantime, prescribers can continue to consider equivalent preparations that provide a similar dose to that which their patient is using. If an exact match is not possible, prescribers can seek guidance available on our interactive chart and on the practical prescribing chart on the BMS website (pdf) , to clarify equivalent doses.
Consideration could also be given to prescribing estrogen and progestogen separately to make the closest match or find a suitable alternative.
Different brands for the same medication may vary in appearance or excipients. However, they would provide equivalent amounts of hormones when used in similar doses.
BMS members can post prescribing queries on the BMS forum if any clarifications are required.
The information on stock availability and supplies was obtained from the pharmaceutical companies producing these products and can be seen in full on The BMS website article.
HRT supply issues - 30 May 2019
There are currently (30 May 2019) supply issues with some HRT products but we are reassured that some issues are temporary.
Meanwhile, equivalent types can be found by looking at the oestrogen and progestogen component and matching it as closely as possible to another brand.
An example is Kliofem instead of Elleste Duet Conti. In some instances an exact match is not possible and our interactive chart will help to clarify equivalent types and doses. Sometimes it will be necessary to prescribe the oestrogen and progestogen separately to make the closest match or find a suitable alternative.
Menopause Matters Magazine and Information Cards
You can email us below to request Information Cards and magazines for distribution to your patients.
Please let us know the following information:
- Organisation Address
- Phone number
- If you're requesting cards
- If you're requesting a FREE copy of the Magazine
To bulk order the magazine, download the printable form
Click to visit Post Reproductive Health (formerly Menopause International)